Biocon Share Price

Biocon Share Price Today: On Friday, Biocon opened on the BSE at Rs 392, touching an intra day high of Rs 392 and an intra day low of Rs 380.55, in the trading session so far.

Biocon Q4 Results: Biocon's consolidated revenue increased 26 per cent in the fourth quarter of the fiscal 2020-21 to Rs 2,044 crore, compared to Rs 1,621 crore in the corresponding quarter last year.

On a standalone basis, Biocon's profit plunged 72 per cent annually to Rs 33 crore from Rs 121 crore during the same period last year.

"The cost of the acquisition is Rs 5,91,61,730 for the acquisition of 26 per cent stake on a fully diluted basis in one or more tranches," the Bangalore-based Biocon said in a BSE filing.

Biocon Share: Biocon received approval from the Drugs Controller General of India to market its novel biologic drug Itolizumab for treating patients having Covid-19 complications.

Syngene International's IPO was subscribed over 32 times last month, helping it raise an estimated Rs 550 crore. The company had also raised Rs 150 crore from anchor investors. The IPO had opened on July 27 and closed on July 29.

Syngene International is offering 2.2 crore shares in the price band of Rs 240-Rs 250. The issue is essentially an offer for sale wherein proceeds from the IPO will not be ploughed back in the company. Its parent Biocon is selling 11 per cent stake in the company which will bring down its stake to 74.5 per cent from 85.5 per cent now.

Biocon Share Price Today: On Friday, Biocon opened on the BSE at Rs 392, touching an intra day high of Rs 392 and an intra day low of Rs 380.55, in the trading session so far.

Biocon Q4 Results: Biocon's consolidated revenue increased 26 per cent in the fourth quarter of the fiscal 2020-21 to Rs 2,044 crore, compared to Rs 1,621 crore in the corresponding quarter last year.

On a standalone basis, Biocon's profit plunged 72 per cent annually to Rs 33 crore from Rs 121 crore during the same period last year.

"The cost of the acquisition is Rs 5,91,61,730 for the acquisition of 26 per cent stake on a fully diluted basis in one or more tranches," the Bangalore-based Biocon said in a BSE filing.

Biocon Share: Biocon received approval from the Drugs Controller General of India to market its novel biologic drug Itolizumab for treating patients having Covid-19 complications.

Syngene International's IPO was subscribed over 32 times last month, helping it raise an estimated Rs 550 crore. The company had also raised Rs 150 crore from anchor investors. The IPO had opened on July 27 and closed on July 29.

Syngene International is offering 2.2 crore shares in the price band of Rs 240-Rs 250. The issue is essentially an offer for sale wherein proceeds from the IPO will not be ploughed back in the company. Its parent Biocon is selling 11 per cent stake in the company which will bring down its stake to 74.5 per cent from 85.5 per cent now.